248 related articles for article (PubMed ID: 21490338)
1. Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression.
Lucas CM; Harris RJ; Giannoudis A; Copland M; Slupsky JR; Clark RE
Blood; 2011 Jun; 117(24):6660-8. PubMed ID: 21490338
[TBL] [Abstract][Full Text] [Related]
2. CIP2A is overexpressed and involved in the pathogenesis of chronic myelocytic leukemia by interacting with breakpoint cluster region-Abelson leukemia virus.
Wang J; Huang T; Sun J; Yu Y; Liu Z; Li W; Jia J; Chen C
Med Oncol; 2014 Aug; 31(8):112. PubMed ID: 25023053
[TBL] [Abstract][Full Text] [Related]
3. Second generation tyrosine kinase inhibitors prevent disease progression in high-risk (high CIP2A) chronic myeloid leukaemia patients.
Lucas CM; Harris RJ; Holcroft AK; Scott LJ; Carmell N; McDonald E; Polydoros F; Clark RE
Leukemia; 2015 Jul; 29(7):1514-23. PubMed ID: 25765543
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a Novel CIP2A Variant (NOCIVA) with Clinical Relevance in Predicting TKI Resistance in Myeloid Leukemias.
Mäkelä E; Pavic K; Varila T; Salmenniemi U; Löyttyniemi E; Nagelli SG; Ammunét T; Kähäri VM; Clark RE; Elo LL; Bachanaboyina VK; Lucas CM; Itälä-Remes M; Westermarck J
Clin Cancer Res; 2021 May; 27(10):2848-2860. PubMed ID: 33674272
[TBL] [Abstract][Full Text] [Related]
5. c-Myc inhibition decreases CIP2A and reduces BCR-ABL1 tyrosine kinase activity in chronic myeloid leukemia.
Lucas CM; Harris RJ; Giannoudis A; Clark RE
Haematologica; 2015 May; 100(5):e179-82. PubMed ID: 25661443
[No Abstract] [Full Text] [Related]
6. Over-expression of cancerous inhibitor of PP2A (CIP2A) in bone marrow cells from patients with a group of high-risk myelodysplastic syndromes.
Li N; Abe S; Kurata M; Abe-Suzuki S; Onishi I; Kirimura S; Murayama T; Hidaka M; Kawano F; Kitagawa M
Pathol Oncol Res; 2014 Apr; 20(2):399-407. PubMed ID: 24163288
[TBL] [Abstract][Full Text] [Related]
7. The role of CIP2A in cancer: A review and update.
Soofiyani SR; Hejazi MS; Baradaran B
Biomed Pharmacother; 2017 Dec; 96():626-633. PubMed ID: 29035828
[TBL] [Abstract][Full Text] [Related]
8. Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression.
Liu CY; Huang TT; Chen YT; Chen JL; Chu PY; Huang CT; Wang WL; Lau KY; Dai MS; Shiau CW; Tseng LM
EBioMedicine; 2019 Feb; 40():263-275. PubMed ID: 30651219
[TBL] [Abstract][Full Text] [Related]
9. Micropeptide CIP2A-BP encoded by LINC00665 inhibits triple-negative breast cancer progression.
Guo B; Wu S; Zhu X; Zhang L; Deng J; Li F; Wang Y; Zhang S; Wu R; Lu J; Zhou Y
EMBO J; 2020 Jan; 39(1):e102190. PubMed ID: 31755573
[TBL] [Abstract][Full Text] [Related]
10. Chk1 targeting reactivates PP2A tumor suppressor activity in cancer cells.
Khanna A; Kauko O; Böckelman C; Laine A; Schreck I; Partanen JI; Szwajda A; Bormann S; Bilgen T; Helenius M; Pokharel YR; Pimanda J; Russel MR; Haglund C; Cole KA; Klefström J; Aittokallio T; Weiss C; Ristimäki A; Visakorpi T; Westermarck J
Cancer Res; 2013 Nov; 73(22):6757-69. PubMed ID: 24072747
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of cancerous inhibitor ofPP2A (
Hasanin R; Mossallam G; Elfishawi S; Rabea A; Hamdy N
Expert Rev Hematol; 2022 May; 15(5):465-471. PubMed ID: 35502616
[TBL] [Abstract][Full Text] [Related]
12. FL118 inhibits viability and induces apoptosis of colorectal cancer cells via inactivating the CIP2A/PP2A axis.
Lin X; Gao M; Zhang A; Tong J; Zhang X; Su Q; Yang Z; Gao H; Jiang G
Life Sci; 2019 Dec; 239():117074. PubMed ID: 31751585
[TBL] [Abstract][Full Text] [Related]
13. Cucurbitacin B induces inhibitory effects via the CIP2A/PP2A/C-KIT signaling axis in t(8;21) acute myeloid leukemia.
Ma W; Xiang Y; Yang R; Zhang T; Xu J; Wu Y; Liu X; Xiang K; Zhao H; Liu Y; Si Y
J Pharmacol Sci; 2019 Apr; 139(4):304-310. PubMed ID: 30852180
[TBL] [Abstract][Full Text] [Related]
14. High CIP2A levels correlate with an antiapoptotic phenotype that can be overcome by targeting BCL-XL in chronic myeloid leukemia.
Lucas CM; Milani M; Butterworth M; Carmell N; Scott LJ; Clark RE; Cohen GM; Varadarajan S
Leukemia; 2016 Jun; 30(6):1273-81. PubMed ID: 26987906
[TBL] [Abstract][Full Text] [Related]
15. CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells.
Chen KF; Liu CY; Lin YC; Yu HC; Liu TH; Hou DR; Chen PJ; Cheng AL
Oncogene; 2010 Nov; 29(47):6257-66. PubMed ID: 20729919
[TBL] [Abstract][Full Text] [Related]
16. Cancerous inhibitor of protein phosphatase 2A, an emerging human oncoprotein and a potential cancer therapy target.
Khanna A; Pimanda JE; Westermarck J
Cancer Res; 2013 Nov; 73(22):6548-53. PubMed ID: 24204027
[TBL] [Abstract][Full Text] [Related]
17. Chronic Cigarette Smoke Exposure Subdues PP2A Activity by Enhancing Expression of the Oncogene CIP2A.
Nath S; Ohlmeyer M; Salathe MA; Poon J; Baumlin N; Foronjy RF; Geraghty P
Am J Respir Cell Mol Biol; 2018 Dec; 59(6):695-705. PubMed ID: 30011381
[TBL] [Abstract][Full Text] [Related]
18. TOPK is regulated by PP2A and BCR/ABL in leukemia and enhances cell proliferation.
Uchida E; Suwa S; Yoshimoto R; Watanabe K; Kasama T; Miura O; Fukuda T
Int J Oncol; 2019 May; 54(5):1785-1796. PubMed ID: 30864683
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic nexus of cancerous inhibitor of protein phosphatase 2A (CIP2A): an oncoprotein with many hands.
De P; Carlson J; Leyland-Jones B; Dey N
Oncotarget; 2014 Jul; 5(13):4581-602. PubMed ID: 25015035
[TBL] [Abstract][Full Text] [Related]
20. CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes.
Niemelä M; Kauko O; Sihto H; Mpindi JP; Nicorici D; Pernilä P; Kallioniemi OP; Joensuu H; Hautaniemi S; Westermarck J
Oncogene; 2012 Sep; 31(39):4266-78. PubMed ID: 22249265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]